Risdiplam Intermediate CAS NO.2133298-74-3

 Compound RISDIPLAM; 7-(4,7-Diaza[2.5]OCT-7-YL)-2-(2,8-dimethylimidazol[1,2-B]pyridin-6-yl)-4H-PYRIDO[1,2-A]pyrimidine-4-one; Ristiran reagent raw materials

7-amino-2,3-dihydro-1H-inden-4-ol; Risdiplam; RO7034067; RG7916; 4H-Pyrido[1,2-a]pyrimidin-4-one,7-(4,7-diazaspiro[2.5]oct-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-; 2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)-7-(4,7-diazaspiro[2.5]octan-7-yl)-4H-pyrido[1,2-a]pyrimidin-4-one; Risdiplam(RG-7916,RO-7034067)

Risdiplam (Evrysdi, RG7916, RO7034067) is an orally administered modifier of SMN2 pre-mRNA splicing that is distributed to the central nervous system (CNS) and surrounding tissues.

Xuzhou Maikai Biotechnology Co., Ltd. was established in November 2021 with a registered capital of 15 million yuan. It is an emerging R&D enterprise based on anti-tumor drugs and biotechnology. The company cooperates with Dalian University of Technology, Zhejiang University, Jinan University, etc. Colleges and universities have good cooperative relations. The founders and shareholders of the company have 20 years of working experience in the chemical industry. They have in-depth understanding and control of the product market. The technology is mature and advanced, and the product quality has reached the pharmaceutical level, which has been fully recognized by customers in the industry.

The company focuses on the biochemical industry, aspires to become the world's leading brand in this industry, and contributes to the cause of human health. Since its establishment, the company has always adhered to and adhered to the core business philosophy of "morality-based, honesty-first", and regards providing value to customers as our responsibility, which has won praise from customers.